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The validity of screening based on spot morning urine sam-
ples to detect subjects with microalbuminuria in the general
population.
Background. No study has yet investigated the validity of
prescreening by albumin measurements in a spot morning
urine sample to identify in the general population subjects
with microalbuminuria. We therefore tested the diagnostic
performance of urinary albumin concentration (UAC) and
albumin-creatinine ratio (ACR), measured in a spot morning
urine sample, in predicting a urinary albumin excretion (UAE)
≥30 mg in subsequent 24-hour urines (microalbuminuria).
Methods. Subjects (2527) participating in the PREVEND
study, a representative sample from the general population, col-
lected a spot morning urine sample and, on average, 77 days
later, two 24-hour urine collections.
Results. The ROC curve of UAC in predicting microalbumin-
uria has an area-under-the-curve of 0.92 with a discriminator
value of 11.2 mg/L. Using this cut-off value for UAC, sensi-
tivity in predicting microalbuminuria is 85.0%, and specificity
85.0%. For ACR these values are, respectively: area-under-the-
curve 0.93, discriminator value 9.9 mg/g, sensitivity 87.6%, and
specificity 87.5%. Sensitivity for UAC in predicting microal-
buminuria does not differ significantly from the sensitivity for
ACR, whereas the difference between the specificities of UAC
and ACR reaches statistical significance, but is numerically very
small. In various subgroups characterized by differences in uri-
nary creatinine excretion, the area-under-the-ROC curve, sensi-
tivity, as well as specificity, do not increase relevantly compared
to the results in the overall study population. This holds true for
ACR as well as UAC.
Conclusion. The diagnostic performance of measuring UAC
in a spot morning urine sample in predicting microalbumin-
uria in subsequent 24-hour urine collections is satisfactory, and,
moreover, comparable to that of measuring ACR. In order to
keep the burden and costs involved in population screening for
microalbuminuria as low as possible, we therefore propose pre-
screening by measuring UAC in a spot morning urine sample.
Those subjects with a UAC above a certain predefined level
(e.g., 11 mg/L) should be asked to collect timed urine samples.
Key words: albuminuria, microalbuminuria, creatinine, screening, sen-
sitivity, specificity, PREVEND.
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In patients with type 1, as well as type 2 diabetes
mellitus, the presence of a urinary albumin excretion
≥30 mg/24-hour is highly predictive for later occurrence
of cardiovascular disease [1–4]. Evidence is accumulating
that in the general population a similar association exists
[5–7]. The risk for cardiovascular events entailed by al-
buminuria seems at least partly independent from serum
cholesterol and blood pressure [3, 7]. These results in-
dicate that in the general population mass screening for
the presence of abnormal urinary albumin excretion may
be a useful strategy to identify people at high risk for
cardiovascular events who may benefit from preventive
strategies.
The reference method to measure urinary albumin ex-
cretion is a 24-hour urine collection (UAE) [8, 9]. In
mass screening, however, such a method is impractical.
This would imply that huge numbers of individuals would
have to undergo the cumbersome procedure of a 24-hour
urine collection. A solution to this problem would be
that first a spot morning urine collection is performed.
In this spot morning urine collection, albumin concentra-
tion (UAC) or albumin-creatinine ratio (ACR) can be de-
termined. Subsequently, only those people with an UAC
or ACR above a certain predefined value would be in-
vited to collect a 24-hour urine. To our knowledge, no
study has yet investigated the validity of albumin mea-
surements from a spot morning urine sample to iden-
tify in the general population subjects with abnormal
urinary albumin excretion in a subsequent 24-hour urine
collection.
The PREVEND study has collected in the general
population spot morning urine samples and 24-hour
urines on separate occasions. We tested the diagnostic
performance of measuring UAC and ACR in the spot
morning urine samples to predict albuminuria in the sub-
sequent 24-hour urine collections. In addition, we tested
whether UAC and ACR in this respect behave differently
in subgroups known for higher creatinine production
rate.
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METHODS
Study population
This study was performed in the subjects participat-
ing in the Prevention of Renal and Vascular ENd-stage
Disease (PREVEND) study. The PREVEND study is
designed to prospectively investigate the natural course
of increased levels of urinary albumin excretion and its
relation to renal and cardiovascular disease in a large
cohort drawn from the general population. Details of
this protocol have been described elsewhere [10, 11].
In summary, in the period 1997 to 1998, all inhabitants
of the city of Groningen, The Netherlands, aged 28 to
75 years, were sent a 1-page postal questionnaire and
a vial to collect an early morning urine sample (N =
85,421). Of these subjects, 40,856 responded (47.8%) and
sent a vial to a central laboratory where urinary albu-
min and creatinine concentrations were measured. Af-
ter exclusion of subjects with type 1 DM (defined as the
use of insulin) and pregnant women, all subjects with
a UAC of ≥10 mg/L (N = 6000) and a randomly se-
lected control group with UAC <10 mg/L (N = 2592)
were invited for further investigations in an outpatient
clinic and to collect two consecutive 24-hour urines. These
8592 subjects form the PREVEND cohort. Because es-
timation of the diagnostic performance of the proposed
tests would be biased by the fact that the PREVEND
cohort is enriched for subjects with albuminuria, we
reweighted the oversampled part (UAC of ≥10 mg/L)
by proportionally taking a computer-generated random
subset. Subjects were excluded when leukocyturia or ery-
throcyturia was present because this makes albumin mea-
surement unreliable (leukocytes >75/lL, or erythrocytes
>50 erythrocytes/lL, or leukocytes = 75, and erythro-
cytes >5/lL measured by dipstick in the 24-hour urines),
and when subjects were known with proteinuria or re-
nal disease. Thus, a study population of 2527 subjects
was created that is a representative sample of the gen-
eral population.
Study design
The screening program in the outpatient clinic con-
sisted of two visits [10, 11]. At the first visit, participants
completed a self-administered extended questionnaire
regarding demographics. Furthermore, blood pressure
and anthropometric measurements (weight and height)
were performed, blood was drawn in fasting condition,
and subjects were asked to collect 24-hour urine on two
consecutive days. Oral and written instructions on how
to collect 24-hour urine were given, and subjects were in-
structed to postpone urine collection in case of urinary
tract infection or menstruation, and to refrain as far as
possible from heavy exercise during the collection pe-
riod. Furthermore, the subjects were asked to store the
urine cold (4◦C) for a maximum of 4 days prior to the
second visit. Measurements of urinary volume, albumin,
and creatinine concentration were performed on each
collection. All subjects gave written informed consent.
The PREVEND study was approved by the local medi-
cal ethics committee, and is conducted in accordance with
the guidelines of the Declaration of Helsinki.
Analytical methods
Urinary albumin excretion was determined by neph-
elometry, with a threshold of 2.3 mg/L and intra- and
interassay coefficients of variation of 2.2% and 2.6%, re-
spectively (BNII, Dade Behring Diagnostica, Marburg,
Germany). UAE was calculated as the average urinary al-
bumin excretion in the two consecutive 24-hour urine col-
lections. Creatinine assessment in urine was determined
by Kodak Ektachem dry chemistry (Eastman Kodak,
Rochester, NY, USA), an automatic enzymatic method.
The intra- and interassay coefficients of variation were
0.9% and 2.9%, respectively. Urinary leukocyte and ery-
throcyte measurements were performed by Nephur-test
and leuko-sticks (Boehringer Mannheim, Mannheim,
Germany).
Statistical analysis
Sensitivity and specificity were calculated to determine
the diagnostic properties of ACR and UAC (measured in
the spot morning urine collection) in predicting a UAE
≥30 mg/24-hour (measured in 24-hour urine collections).
Determination of the confidence intervals for sensitiv-
ity and specificity was performed using the guidelines of
Gardner and Altman [12]. ROC curves were calculated
to compare the discriminative power of ACR and UAC.
The ROC curve analysis was also used to determine dis-
criminator values for ACR and UAC. The value lying
nearest to the point on intersection of the ROC curve
and the 100%-to-100% diagonal was chosen as discrim-
inator value. For UAC and ACR, the true positive rate
(TPR) was calculated as a/(a+b), the false positive rate
as b/(a+b), and the false negative rate as c/(c+d), where
a is the number of positive tests with subsequent UAE
≥30 mg/24-hour, b is the number of positive test results
with UAE <30 mg/24-hour, c is the number of negative
test results with UAE ≥30 mg/24-hour, and d is the num-
ber of negative test results with UAE <30 mg/24-hour
[13].
It is known from literature that some anthropomor-
phic/demographic variables influence muscle mass, and
thus, urinary creatinine excretion, which is included in
the ACR [14–17]. Therefore, multiple regression analysis
was performed with 24-hour urinary creatinine excretion
as dependent variable, to test whether, and if so, which
of these variables had a statistically significant impact on
24-hour urinary creatinine excretion in our study. The in-
dependent variables tested were gender, age, weight, and
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Table 1. Characteristics of participating subjects
Number 2527
Gender (male, %) 47.1
Age years 48.8 (48.3–49.3)
Weight kg 77.2 (76.7–77.7)
Height cm 172.9 (172.5–173.3)
Race (Caucasian, %) 95.4
Smoking % 34.3
CVD history % 11.4
Type 2 DM % 2.6
Use of BP lowering agents % 9.5
SBP mm Hg 126.2 (125.5–126.9)
DBP mm Hg 72.8 (72.4–73.2)
Use of lipid lowering agents % 6.6
Serum cholesterol mmol/L 5.63 (5.59–5.66)
Serum creatinine lmol/L 83.2 (82.6–83.8)
Spot morning UAC mg/L 5.9 (3.6–9.8)
Spot morning ACR mg/g 4.9 (3.7–7.6)
24-hr UAE mg/24-hr 7.0 (5.4–10.5)
Data are given as means with 95% confidence intervals, with the exception of
spot morning urinary albumin concentration (UAC), albumin-creatinine ratio
(ACR), and 24-hour urinary albumin excretion (UAE), which are given as
medians with interquartile range. Other abbreviations are: CVD, cardiovascular
disease; DM, diabetes mellitus; BP, blood pressure; SBP, systolic blood pressure;
DBP, diastolic blood pressure.
race. Subsequently, it was analyzed whether these anthro-
pomorphic variables influence the discriminator values
of ACR and UAC. For continuous variables, the over-
all population was divided in two subgroups, equal to
or above the median value and under the median value.
Student t test (or Welch t test in case SDs were statisti-
cally significantly different) was used to test differences
of sensitivity/specificity of ACR versus UAC in predict-
ing UAE ≥30 mg/24-hour. Data are given as means plus
95% confidence intervals (95% CI). In case of skewed
distribution (UAC, ACR, and UAE), medians are given
with interquartile range. A value of P < 0.05 (two-sided)
was used as the nominal level of statistical significance.
Calculations were performed using the statistical pack-
age SPSS, version 11.5, for Windows (Statistical Package
for the Social Sciences, Chicago, IL, USA).
RESULTS
Altogether, 2527 subjects were included. Table 1 shows
the characteristics of the study population. The preva-
lence of a UAE ≥30 mg/24-hour was 6.1%. The mean
time between the spot morning urine collection and the
collection of the 24-hour urines was 77 days.
Figure 1 shows the diagnostic performance of a spot
morning urine UAC in predicting a UAE ≥30 mg in sub-
sequent 24-hour urine collections. The ROC curve has an
area-under-the-curve of 0.92, and the discriminator value
is 11.2 mg/L. Using this cut-off value for UAC, sensitiv-
ity in predicting a UAE ≥30 mg/24-hour is 85.0% (79.3–
90.6), and specificity 85.0% (83.5–86.4). For ACR these
values are, respectively: area-under-the-curve 0.93, dis-
criminator value 9.9 mg/g, sensitivity 87.6% (82.4–92.8),
and specificity 87.5% (86.2–88.9) (Fig. 2). Sensitivity for
UAC in predicting UAE ≥30 mg/24-hour does not differ
significantly from the sensitivity for ACR, whereas the
difference between the specificities of UAC and ACR is
numerically small, but does reach statistical significance
(Table 2).
Multiple regression analysis revealed that, in order
of significance, gender, age, weight, and race were sta-
tistically significantly associated with urinary creatinine
excretion (R2 0.55, P < 0.001). Table 2 shows the re-
sults for diagnostic performance of UAC and ACR in
a spot morning urine sample in predicting a 24-hour uri-
nary albumin excretion ≥30 mg. Data are given for both
the overall study population, as well as for various sub-
groups when subdivided according to these anthropomor-
phic/demographic variables. Because diabetic subjects
have a higher prevalence of elevated urinary albumin ex-
cretion, we also calculated the diagnostic performance
of UAC and ACR for diabetic and nondiabetic subjects
separately. Using subgroup-specific discriminator values,
it appears that in these subgroups, the area-under-the-
ROC curve, sensitivity, as well as specificity, does not in-
crease relevantly compared to the results in the overall
study population. This holds true for both ACR, as well
as UAC. Of note, subgroup-specific discriminator values
differ less for UAC when compared to ACR.
The robustness of our results was tested by generating
a second data set. From our overall population, another
random sample representative for the general popula-
tion was drawn. In this second sample, the prevalence of
albuminuria in excess of 30 mg/24-hour is 6.0% (versus
6.1% in the first data set, P = NS). The diagnostic perfor-
mance of UAC in a spot morning urine sample in predict-
ing UAE ≥30 mg/24-hour is similar: the area under the
ROC-curve being 0.92 (versus 0.92 in the first data set,
P = NS), and the discriminator value 12.4 mg/L (versus
11.2 mg/L in the first data set). Sensitivity and specificity
for UAC at the discriminator value is 86.3% (80.8–91.7%)
and 86.3% (84.9–87.6%), respectively. Both values are
not statistically different from values obtained in the first
data set. For ACR, the area under the ROC curve in the
second data set is 0.93 (versus 0.93 in the first data set,
P = NS), and the discriminator value 9.9 mg/g (versus
9.9 mg/g in the first data set). Sensitivity and specificity
for ACR at the discriminator value is 86.3% (80.8–91.7%)
and 86.3% (85.0–87.7%), respectively. Both values are,
again, not statistically different from values obtained in
the first data set.
Traditionally, a cut-off value for UAC of ≥20 mg/L has
been used to indicate a UAE ≥30 mg/24-hour. Using this
cut-off value in our data set we obtain low sensitivity, but
high specificity (Table 3). For ACR, the traditionally used
cut-off value indicating a UAE ≥30 mg/24-hour has been
30 mg/g. For this cut-off value, sensitivity again is low,
whereas specificity is high (Table 3). Later, based on the
observation that there are differences between males and
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Fig. 1. Diagnostic performance of urinary albumin concentration in a spot morning urine sample (UAC) in predicting microalbuminuria in sub-
sequent 24-hour urines excretion of ≥30 mg (UAE). A receiver operating characteristics (ROC) curve is shown on the left. Two arbitrary cut-off
values for UAC (in mg/L) are shown by markers and values. The value lying on the intersection of the ROC curve and the 100%-to-100% diag-
onal is defined “discriminator value” (DV). Sensitivity and specificity for a number of UAC cut-off values are shown on the right (Table). Other
abbreviations are: AUC, area-under-the-curve; TPR, true positive rate; FPR, false positive rate; FNR, false negative rate.
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Fig. 2. Diagnostic performance of albumin-creatinine ratio in a spot morning urine sample (ACR) in predicting microalbuminuria in subsequent
24-hour urines. A receiver operating characteristics (ROC) curve is shown on the left. Two arbitrary cut-off values for ACR (in mg/g) are shown by
markers and values. The value lying on the intersection of the ROC curve and the 100%-to-100% diagonal is defined “discriminator value” (DV).
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females in urinary creatinine excretion, gender specific
cut-off values for ACR were proposed by Warram et al:
for males, an ACR ≥17 mg/g and for females an ACR
≥25 mg/g [18]. Using these gender specific cut-off values,
sensitivity in males and females increases, but remains
low, whereas specificity is hardly affected (Table 3).
DISCUSSION
Our data indicate that in the general population UAC
and urinary ACR measured in a spot morning urine
sample have satisfying, and numerically similar, power
to predict which individuals will have a 24-hour UAE
≥30 mg/24-hour in subsequent 24-hour urine collections.
Furthermore, our data suggest that applying traditionally
used cut-off values for UAC and ACR results in low sen-
sitivity, and thus, in a relatively large percentage of false-
negative test results for predicting microalbuminuria.
In the general population, only few studies have been
devoted to the evaluation of UAC and ACR versus timed
urine collection procedures [14, 19–23]. Most of these
involved only small numbers of subjects, with the conse-
quence that confidence intervals for sensitivity and speci-
ficity are wide [14, 19, 21–23]. More important, nearly all
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of these studies are hampered by the fact that they, unlike
the procedure to be followed in mass screening, used a
portion of a 24-hour urine collection to measure UAC or
ACR and the same 24-hour urine collection for determi-
nation of the reference value UAE. This way of analyz-
ing data addresses another question, that being whether
a spot morning urine sample can replace a 24-hour urine
collection. It is expected to result in falsely high values
for sensitivity and specificity because it does not take into
account day-to-day variability in albuminuria. Thus, to
our knowledge, our study is the first to investigate the
validity of albumin measurements from a spot morning
urine sample to identify in the general population subjects
with abnormal urinary albumin excretion in subsequent
24-hour urine collections.
Theoretically, mass screening to identify subjects with
a UAE ≥30 mg/24-hour by measuring UAC has the dis-
advantage that this latter parameter is influenced by
variations in urinary volume. When urine is more con-
centrated, the concentration of albumin is higher and vice
versa. Therefore, a loss of specificity and sensitivity might
be expected. For this reason, the urinary albumin con-
centration can be divided by the urinary creatinine con-
centration (ACR ratio), thus correcting for variations in
urinary volume. The disadvantage of the use of ACR is,
however, that additional measurement of urinary creati-
nine is needed at the expense of extra costs and additional
variability, the amount depending on the creatinine mea-
surement, per se, and on interindividual differences in
urinary creatinine excretion. Our data suggest that there
is hardly any difference in power of UAC versus ACR
in predicting a UAE ≥30 mg/24-hour: the areas under
both ROC curves are good and nearly similar (0.92 ver-
sus 0.93, respectively, P = NS). Moreover, sensitivity and
specificity for both indicators are acceptable (Figs. 1 and
2). When we defined specific subgroups according to dif-
ferences in creatinine generation rate in order to try to
improve the diagnostic performance of ACR in predict-
ing an abnormal 24-hour urinary albumin, the AUC, sen-
sitivity, and specificity for ACR in each subgroup was not
relevantly higher than in the overall population. These
results were corroborated in our second data set. Deter-
mination of creatinine in large numbers of spot morning
urine samples obtained in mass screening will result in
substantial costs, the exact amount of which will vary per
laboratory. In order to keep costs and the burden involved
in mass screening for microalbuminuria as low as possi-
ble, we therefore propose prescreening by measuring in a
spot morning urine sample only urinary albumin concen-
tration. Those subjects with a urinary albumin concentra-
tion above a certain predefined level should be asked to
collect 24-hour urines.
We want to emphasize that the use of UAC over ACR
is a cheaper test with a comparable ability to screen for
disease. Its utility is purely as a screening tool. Monitoring
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Table 3. Diagnostic performance of traditionally used cut-off values for urinary albumin concentration (UAC) and albumin-creatinine ratio
(ACR) in predicting microalbuminuria in subsequent 24-hour urines
(Sub)group Cut-off value Sensitivity % Specificity % TPR FPR FNR
UAC All ≥20 mg/L 69.3 (62.0–76.6) 95.8 (95.0–96.6) 106/205 (52%) 99/205 (48%) 47/2322 (2.0%)
ACR All ≥30 mg/g 49.0 (71.1–56.9) 98.7 (98.2–99.1) 75/107 (70%) 32/107 (30%) 78/2420 (3.2%)
Male specific ≥17 mg/g 73.2 (64.4–82.0) 97.8 (96.9–98.7) 71/95 (75%) 24/95 (25%) 26/1094 (2.4%)
Female specific ≥25 mg/g 51.8 (38.7–64.9) 97.7 (96.8–98.5) 29/59 (49%) 30/59 (51%) 27/1279 (2.1%)
All gender specific 65.4 (57.8–72.9) 97.7 (97.1–98.3) 100/154 (65%) 54/154 (35%) 53/2373 (2.1%)
Abbreviations are: TPR, true positive rate; FPR, false positive rate; FNR, false negative rate. Values for sensitivity and specificity are given as means and 95%
confidence intervals.
False positive rate
N = 99/205 (48%)
False negative rate
N = 47/2322 (2.0%)
True positive rate
N = 106/205 (52%)
False positive rate
N = 372/505 (74%) False negative rateN = 20/2022 (1.3%)
True positive rate
N = 133/505 (26%)
A B
Fig. 3. Venn diagrams for screening on urinary albumin concentration (UAC) in a spot morning urine collection to identify subjects with microal-
buminuria in subsequent 24-hour urine collections. Diagram A shows the situation in the general population (N = 2527), with the traditionally used
cut-off value of 20 mg/L. The hatched circle represents individuals with a positive test result (spot morning UAC ≥20 mg/L, N = 205), whereas the
solid gray circle represents individuals with a positive “gold standard” (24-hour urine collection UAE ≥30 mg, N = 153). Diagram B shows the
situation when in the same population the cut-off value 11 mg/L is chosen. Now, 505 people have a positive test result (UAC ≥11 mg/L).
individual patients over time is another issue. It may well
be that in this case UAC may be not useful due to varia-
tions caused by changes in urinary volume, whereas ACR
due to relatively parallel changes in urinary creatinine
concentration may be more helpful in patient monitoring.
The next question to be addressed is which cut-off value
for UAC to use. Traditionally, the cut-off value indicat-
ing a UAE ≥30 mg/24-hour has been 20 mg/L [8, 9]. This
specific value has been derived from studies performed
in diabetic subjects that plotted UAC versus UAE [24].
Regression analysis in these studies showed that a UAE
of 30 mg/24-hour corresponded with a UAC of approx-
imately 20 mg/L. It is questionable whether this value,
derived from studies in diabetic individuals, will be simi-
lar to the one in the general population. More important,
it should again be noted that these studies used the same
urine collection to measure UAE and UAC, not taking
into account day-to-day variability in albuminuria [24].
In contrast, in our study, the spot morning urine sam-
ple is used to predict which individuals have an abnor-
mal urinary albumin excretion in a subsequent 24-hour
urine collection. In this setting, using the traditional UAC
cut-off value of 20 mg/L to identify subjects “at risk” for
abnormal albuminuria, specificity appears high (95.8%),
whereas sensitivity is low (69.3%). Consequently, the
number of false-negative test results is unacceptably high
(47 out of 153 subjects with a UAE ≥30 mg/24-hour would
not be detected, Fig. 3). In order to meet the requirements
for mass screening, the number of false negatives should
be as low as possible. On the other hand, decreasing the
percentage of false-negative test results is expected to
result in increases in the percentage of false positives.
Since the “penalty” of being false positive is merely that a
24-hour urine collection has to be performed, we think
that a relatively large number of false-positive test re-
sults is acceptable. Based on our findings, we therefore
propose that an UAC cut-off value of 11 mg/L should
be used for mass screening in the general population to
identify subjects that will have a UAE ≥30 mg/24-hour.
Using this cut-off value, the percentage of false-negative
test results drops. Now only 20 out of 153 subjects with a
UAE ≥30 mg/24-hour are not detected (Fig. 3).
The concept of screening for abnormal urinary albu-
min excretion is only worthwhile when interventions to
reduce the high number cardiovascular events in subjects
with this condition are possible and of proven clinical ben-
efit. Of interest, subgroup analysis of the HOPE study, a
recent large-scale, randomized, controlled trial, showed
that in those subjects with higher baseline levels of albu-
minuria, intervention with an ACE inhibitor is of particu-
lar value. This held true both in diabetic and nondiabetic
patients [25, 26]. Furthermore, we recently completed a
randomized, controlled trial that was especially designed
to investigate this issue: the PREVEND IT study [27]. In
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this study, 864 normotensive, normocholesterolemic sub-
jects with a UAE ≥30 mg/24-hour were treated in a 2 ×
2 factorial design with the ACE inhibitor fosinopril or
placebo, and the HMG CoA reductase inhibitor pravas-
tatin or placebo. It was shown that the ACE inhibitor low-
ered albuminuria by 30% and reduced the relative risk for
the combined primary outcome parameter of cardiovas-
cular morbidity and mortality by 44% (P = 0.07). In this
study, the beneficial effect of the ACE inhibitor was de-
pendent of the baseline value of albuminuria: the higher
albuminuria, the more protective the effect of the ACE
inhibitor [26]. Further studies to confirm the clinical ben-
efit of intervention based on the presence of albuminuria
are needed.
Such studies should also address the issue of cost effec-
tiveness of mass screening of the general population with
subsequent intervention. Recently, Boulware et al con-
cluded that a strategy of annual screening for proteinuria
by primary care physicians, with follow-up testing and
treatment with ACE inhibitors, would not be cost effec-
tive to slow progression of kidney disease [28]. However,
the results of this study are strongly influenced by the
low yield of the screening test (looking only for dipstick
positive proteinuria), the high costs for the screening by
the primary care physicians, and the fact that they only
took into account benefits with regard to the prevention
of end-stage renal disease. Our screening approach, mea-
suring UAC in a spot morning urine samples that are sent
in vials by post, looking for microalbuminuria, will result
in more cases per 1000 persons screened, and is more-
over less expensive [29]. Such a screening program may
help to tackle not only the epidemic of end-stage renal
disease, but at the same time, also to lower cardiovascular
morbidity and mortality. We hope that such an approach
will be cost effective. A formal analysis is planned.
One should realize that subjects using insulin, pregnant
women, and subjects with leukocyturia and/or erythrocy-
turia were excluded. Screening for albuminuria is already
accepted clinical practice for insulin-treated diabetics.
Therefore, there is no need for such subjects to take part
in screening of the general population. The same holds
true for pregnant women, in whom albuminuria may in-
crease because of pregnancy-related hyperfiltration, and
may indicate the onset of (pre-)eclampsia. It is gener-
ally accepted that the presence of leukocyturia and/or
erythrocyturia may indicate a urinary tract infection or
bleeding. In such cases, the amount of albuminuria is not
thought to reflect endothelial damage, but merely the re-
sult of infection/bleeding. Such urine samples should not
be used as risk indicators [9, 10]. We therefore are con-
vinced that our results are as robust as possible, of course,
keeping in mind that these results are valid for the Dutch
situation, and should be corroborated in other popula-
tions that may differ in (socio)demographics.
CONCLUSION
We found that the diagnostic performance of measur-
ing urinary albumin concentration in a spot morning urine
sample in predicting an albumin excretion ≥30 mg in sub-
sequent 24-hour urine collections is satisfactory and com-
parable to that of albumin-creatinine ratio. In order to
keep the burden and costs involved in mass screening of
the general population as low as possible, we therefore
propose to measure UAC in a spot morning urine sam-
ple as prescreening. Those subjects with a UAC above a
certain predefined level (e.g., 11 mg/L) should be asked
to collect timed urine samples.
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